#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Rett syndrome Amyotrophic lateral sclerosis gene carrier Exudative retinopathy Cardiac sarcoidosis Myeloid leukaemia Primary amyloidosis Hidradenitis Fusarium infection Encephalitis autoimmune Thromboangiitis obliterans Oesophageal squamous cell carcinoma stage II Dupuytren's contracture Transitional cell carcinoma Peritoneal neoplasm Osteochondrodysplasia More trials…

    Learn about Rare Diseases

    Primary hyperoxaluria – Trials in Disease Pituitary-dependent Cushing’s syndrome – Basic Information Leukoencephalopathy Ornithine transcarbamoylase deficiency – Trials in Disease Congenital generalised lipodystrophy – Diagnostics Mucopolysaccharidosis – Basic Information Primary mediastinal large B-cell lymphoma – Diagnostics Pelizaeus-Merzbacher disease – Basic Information Brain stem glioma – Life with Disease Hairy cell leukaemia recurrent – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Phenol, Liquefied Nemolizumab Izorlisib Mesilate Azd9550 Tobevibart Miglustat Dapansutrile Diclofenac Epolamine Timrepigene Emparvovec Sirolimus Lovastatin Sodium Chloride Bosentan Panitumumab Choriogonadotropin Alfa Lixisenatide Milvexian COBALAMIN Azenosertib A/H1N1 INFLUENZA VACCINE More therapies…

    Learn about Your Condition

    EGFR gene mutation Liver transplant White matter lesion Colitis Lichen planus Hyponatraemia Sickle cell disease Indolent systemic mastocytosis Cholangiosarcoma Biliary tract operation Gestational diabetes Type 2 diabetes mellitus Meniscus operation Stomatitis Candida infection More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Immune System Phenomena

  • Long‑Term Safety and Efficacy of RO7790121 in Adults with Moderate to Severe Rheumatoid Arthritis: Extension Study

    Recruiting

    2 1
    Investigated Diseases:
    • Rheumatoid arthritis
    Investigated Drugs:
    • Ro7790121
    Belgium Denmark France Germany Italy Poland +1

  • Study on the Effectiveness and Safety of RO7790121 for Patients with Moderate to Severe Crohn’s Disease

    Recruiting

    3 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Ro7790121
    Austria Belgium Bulgaria Croatia Czechia France +8

  • A study testing RO7790121 for moderate to severe rheumatoid arthritis in patients who did not respond to or cannot tolerate TNF or JAK inhibitor treatments

    Recruiting

    2 1
    Investigated Drugs:
    • Ro7790121
    Belgium Denmark France Germany Italy Poland +1

  • A study to evaluate the long-term safety and effectiveness of afimkibart in patients with atopic dermatitis who took part in previous afimkibart studies

    Recruiting

    2 1
    Investigated Drugs:
    • Ro7790121
    France Germany Italy Poland Spain

  • A study to evaluate the safety of dazodalibep in patients with Sjögren’s Syndrome over a long period of time

    Recruiting

    3 1 1
    Investigated Diseases:
    • Sjogren’s syndrome
    Investigated Drugs:
    • Dazodalibep
    Belgium Croatia Denmark France Germany Greece +6

  • A Study of Belimumab to Help Identify Safe Kidney Transplant Matches in Patients with High Antibody Levels Against Donor Tissue Types

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Transplant rejection
    Investigated Drugs:
    • Belimumab
    The Netherlands
1 2 3 4
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!